PB272-Kadcyla Combo May Benefit HER2-Positive Breast Cancer Patients, Study Finds
News
A combination of PB272 (neratinib) and Kadcyla (ado-trastuzumab emtansine) may benefit HER2-positive metastatic breast cancer patients who previously received chemotherapy and another combo treatment, a clinical trial indicates. Results of the FB-10 ... Read more